Literature DB >> 10502160

[Ceará State Pharmacovigilance System: a year of experience].

H L Coêlho1, P S Arrais, A P Gomes.   

Abstract

This paper summarizes the first year of activity of the Ceará State Pharmacovigilance System (SIFACE) as a strategy to discuss practical and methodological problems related to developing pharmacovigilance in Brazil. Siface is being structured by the Group for the Prevention of Improper Use of Pharmaceuticals (GPUIM), based on hospital pharmacies. A total of 63 reports (119 suspected adverse drug reactions, or ADRs) were processed, the majority among women (55.7%) and children (34.4%). Antibiotics were the drug group most frequently involved, and the most common reactions were dermatological. In 20% of the cases, patients had been re-exposed to drugs previously reported as producing adverse reactions, thus highlighting the importance of pharmacovigilance to prevent ADRs.

Entities:  

Mesh:

Year:  1999        PMID: 10502160     DOI: 10.1590/s0102-311x1999000300021

Source DB:  PubMed          Journal:  Cad Saude Publica        ISSN: 0102-311X            Impact factor:   1.632


  4 in total

1.  Adverse Drug Reactions and quality deviations monitored by spontaneous reports.

Authors:  Marília Berlofa Visacri; Cinthia Madeira de Souza; Catarina Miyako Shibata Sato; Silvia Granja; Mécia de Marialva; Priscila Gava Mazzola; Patricia Moriel
Journal:  Saudi Pharm J       Date:  2014-07-02       Impact factor: 4.330

2.  Governance and pharmacovigilance in Brazil: a scoping review.

Authors:  Kathy Moscou; Jillian C Kohler; Anita MaGahan
Journal:  J Pharm Policy Pract       Date:  2016-02-08

3.  Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.

Authors:  Mario Javier Olivera; Zulma M Cucunubá; Carlos Arturo Álvarez; Rubén Santiago Nicholls
Journal:  Am J Trop Med Hyg       Date:  2015-09-21       Impact factor: 2.345

4.  Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.

Authors:  Mario J Olivera; Zulma M Cucunubá; Carlos A Valencia-Hernández; Rafael Herazo; Diana Agreda-Rudenko; Carolina Flórez; Sofía Duque; Rubén S Nicholls
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.